Abner Herrman & Brock’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-17,554
| Closed | -$9.13M | – | 56 |
|
|
2024
Q4 | $9.13M | Buy |
17,554
+1,059
| +6% | +$582K | 1.13% | 37 |
|
|
2024
Q3 | $10.2M | Buy |
16,495
+10
| +0.1% | +$5.92K | 1.23% | 36 |
|
|
2024
Q2 | $9.12M | Sell |
16,485
-716
| -4% | -$410K | 1.16% | 36 |
|
|
2024
Q1 | $10M | Sell |
17,201
-183
| -1% | -$103K | 1.25% | 38 |
|
|
2023
Q4 | $9.23M | Sell |
17,384
-1,366
| -7% | -$661K | 1.3% | 37 |
|
|
2023
Q3 | $9.49M | Buy |
18,750
+159
| +0.9% | +$84.7K | 1.45% | 35 |
|
|
2023
Q2 | $9.7M | Sell |
18,591
-6,167
| -25% | -$3.33M | 1.42% | 34 |
|
|
2023
Q1 | $14.3M | Buy |
24,758
+402
| +2% | +$227K | 2.15% | 24 |
|
|
2022
Q4 | $13.4M | Buy |
24,356
+507
| +2% | +$269K | 2.06% | 28 |
|
|
2022
Q3 | $12.1M | Sell |
23,849
-359
| -1% | -$201K | 2.22% | 24 |
|
|
2022
Q2 | $13.2M | Sell |
24,208
-512
| -2% | -$282K | 2.27% | 26 |
|
|
2022
Q1 | $14.6M | Sell |
24,720
-264
| -1% | -$152K | 2.05% | 25 |
|
|
2021
Q4 | $16.7M | Sell |
24,984
-706
| -3% | -$441K | 2.17% | 21 |
|
|
2021
Q3 | $14.7M | Sell |
25,690
-1,324
| -5% | -$727K | 2.07% | 23 |
|
|
2021
Q2 | $13.6M | Sell |
27,014
-59
| -0.2% | -$27.8K | 1.9% | 26 |
|
|
2021
Q1 | $12.4M | Sell |
27,073
-4,080
| -13% | -$1.95M | 1.87% | 26 |
|
|
2020
Q4 | $14.5M | Sell |
31,153
-2,189
| -7% | -$1.03M | 2.26% | 19 |
|
|
2020
Q3 | $14.7M | Sell |
33,342
-1,348
| -4% | -$557K | 2.48% | 12 |
|
|
2020
Q2 | $12.6M | Sell |
34,690
-1,190
| -3% | -$399K | 2.26% | 17 |
|
|
2020
Q1 | $10.2M | Buy |
35,880
+127
| +0.4% | +$40K | 2.3% | 19 |
|
|
2019
Q4 | $11.6M | Sell |
35,753
-4,422
| -11% | -$1.34M | 1.73% | 22 |
|
|
2019
Q3 | $11.7M | Buy |
40,175
+455
| +1% | +$130K | 1.73% | 24 |
|
|
2019
Q2 | $11.7M | Buy |
39,720
+1,181
| +3% | +$325K | 1.67% | 26 |
|
|
2019
Q1 | $10.5M | Buy |
38,539
+279
| +0.7% | +$69.4K | 1.63% | 27 |
|
|
2018
Q4 | $8.56M | Buy |
38,260
+1,632
| +4% | +$383K | 1.56% | 29 |
|
|
2018
Q3 | $8.94M | Sell |
36,628
-202
| -0.5% | -$46.5K | 1.28% | 34 |
|
|
2018
Q2 | $7.63M | Buy |
36,830
+1,670
| +5% | +$354K | 1.19% | 37 |
|
|
2018
Q1 | $7.26M | Buy |
35,160
+2,970
| +9% | +$623K | 1.15% | 34 |
|
|
2017
Q4 | $6.11M | Buy |
32,190
+3,159
| +11% | +$605K | 1.03% | 39 |
|
|
2017
Q3 | $5.49M | Buy |
29,031
+3,296
| +13% | +$597K | 0.97% | 43 |
|
|
2017
Q2 | $4.49M | Sell |
25,735
-109
| -0.4% | -$18.3K | 0.85% | 41 |
|
|
2017
Q1 | $3.97M | Buy |
25,844
+3,970
| +18% | +$607K | 0.79% | 45 |
|
|
2016
Q4 | $3.18M | Buy |
21,874
+3,482
| +19% | +$513K | 0.67% | 48 |
|
|
2016
Q3 | $2.92M | Buy |
18,392
+1,185
| +7% | +$183K | 0.66% | 51 |
|
|
2016
Q2 | $2.62M | Buy |
17,207
+135
| +0.8% | +$19.9K | 0.61% | 51 |
|
|
2016
Q1 | $2.42M | Buy |
17,072
+14,122
| +479% | +$1.89M | 0.61% | 49 |
|
|
2015
Q4 | $418K | Buy |
2,950
+35
| +1% | +$4.67K | 0.22% | 61 |
|
|
2015
Q3 | $365K | Buy |
+2,915
| New | +$380K | 0.19% | 65 |
|
Other funds holding TMO
Abner Herrman & Brock's TMO Position: Q1 2025 in Review
Abner Herrman & Brock sold out of Thermo Fisher Scientific (TMO) in Q1 2025, closing a stake of 17,554 shares — an estimated $9.13M sold.
Abner Herrman & Brock first reported a position in TMO in Q3 2015 and held it in 38 quarters. The position peaked at $16.7M in Q4 2021. 2,571 funds tracked by Wall St. Rank hold TMO as of Q1 2025.
- Abner Herrman & Brock reported no remaining Thermo Fisher Scientific position as of Q1 2025 after selling out during the quarter.
- Abner Herrman & Brock sold 17,554 Thermo Fisher Scientific shares in Q1 2025, an estimated $9.13M.
- Abner Herrman & Brock first reported a position in Thermo Fisher Scientific in Q3 2015 and held it in 38 quarters.
- Abner Herrman & Brock's Thermo Fisher Scientific position peaked at $16.7M in Q4 2021.
- 2,571 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2025.
Based on Abner Herrman & Brock's 13F filing for Q1 2025, filed 8 Apr 2025.